Bosch planning second packaging plant in China
pharmafile | November 7, 2011 | News story | Manufacturing and Production | Bosch, China
Bosch Packaging Technology has decided to boost its presence in Asia with the construction of a second plant in the Sichuan area of China.
Bosch already operates a packaging and processing machinery plant in Hangzhou with around 400 employees, and has now signed an agreement to lease a 66,000 sq. m. plot in Chengdu, Pujiang county, that will eventually boost its headcount in China by another 300 workers.
Chengdu is designed to provide additional capacity when the Hangzhou plant tops out in the next couple of years, said Friedbert Klefenz, Bosch Packaging Technology’s president. The unit is also located near China’s largest production centre for packaging machines.
Production in Chengdu will start early next year thanks to a decision to lease capacity from an existing facility, with construction of the new plant due to start in 2014.
A year later, the first expansion phase will be completed when a building with 13,500 sq. m. footprint – including 7,200 sq. m. of production space – will be ready for occupation.
China has been a strategic market for Bosch for some time, and last year the company unveiled an expansion programme at its Hangzhou plant – first opened in 2006 – which was designed to double production capacity.
The size of the production area was increased to 9,000 sq. m. and the portfolio was expanded to include Bosch’s new high-speed capsule- and vial-filling lines.
The company already makes around a quarter of its turnover from emerging markets, while around 80% of the customers for its Hangzhou plant are local Chinese companies.
Bosch said: “For the current year Bosch Packaging Technology expects to reach sales of around €85 million in the Chinese market with products manufactured either locally or in predominantly European Bosch factories.”
Phil Taylor
Related Content
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
NDA in China receives priority review status for lung cancer treatment
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority …
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission …
